Tian Wang Bu Xin Dan for Insomnia: A Systematic Review of Efficacy and Safety

This systematic review examined the efficacy and safety of Tian Wang Bu Xin Dan (TWBXD) for treating insomnia. The review included randomized controlled trials (RCTs) comparing TWBXD alone or in combination with conventional treatment versus conventional treatment alone or placebo.

Key characteristics of the review: The search covered multiple databases including PubMed, CNKI, and the Cochrane Library. Studies were assessed for quality using the Cochrane Risk of Bias tool. The primary outcome was sleep quality improvement measured by standardized scales such as the Pittsburgh Sleep Quality Index (PSQI).

Number of studies included: The review identified several RCTs, most of which were conducted in China. The total sample size across studies provided reasonable statistical power for meta-analysis, though individual studies were small.

Efficacy: The meta-analysis suggested that TWBXD, either alone or as an adjunct to conventional treatment, was associated with improvements in sleep quality compared to control groups. PSQI scores showed a statistically significant reduction in the TWBXD groups. However, the clinical significance of these improvements was less clear — the magnitude of benefit was moderate at best.

Safety: Adverse event reporting was inconsistent across studies. Some studies reported no adverse events, while others noted mild gastrointestinal discomfort. The long-term safety profile of TWBXD was not adequately addressed by the included studies.

Quality concerns: The review noted several methodological limitations: lack of adequate blinding in most studies, small sample sizes, short follow-up durations, and potential publication bias. The overall quality of evidence was graded as low to moderate.

Severe methodological weaknesses: Most included trials used inadequate randomization procedures and lacked proper blinding. Without blinding, the results are susceptible to performance and detection bias — both patients and assessors knowing the treatment assignment can influence outcomes.

Heterogeneity: The studies varied considerably in their TWBXD formulations, dosages, treatment durations, and co-interventions. This makes it difficult to draw unified conclusions about the formula's efficacy.

Publication bias: As with many TCM systematic reviews, there is concern that studies with positive results are more likely to be published. The review attempted to assess this statistically, but the small number of studies limited the sensitivity of these tests.

Generalizability: All studies were conducted in China, limiting applicability to Western populations. The TCM diagnostic framework used to select patients for TWBXD may not translate to insomnia patients in other healthcare settings.